Status:
COMPLETED
Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Diffuse Large B-cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, ...
Eligibility Criteria
Inclusion
- Patients must have histologically or cytologically confirmed diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma
- Patients must have received no prior anti-lymphoma therapy.
- Age \>18 years.
- Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Patients who have known HIV infection.
- Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 8 2012
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00754117
Start Date
May 1 2008
End Date
December 8 2012
Last Update
May 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College
New York, New York, United States, 10021